Harmony Biosciences Inc. (HRMY)
Harmony Biosciences Statistics
Share Statistics
Harmony Biosciences has 57.03M shares outstanding. The number of shares has increased by 0.46% in one year.
| Shares Outstanding | 57.03M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.35% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 40.49M |
| Failed to Deliver (FTD) Shares | 1.94K |
| FTD / Avg. Volume | 0.25% |
Short Selling Information
The latest short interest is 5.44M, so 9.54% of the outstanding shares have been sold short.
| Short Interest | 5.44M |
| Short % of Shares Out | 9.54% |
| Short % of Float | 13.44% |
| Short Ratio (days to cover) | 12.06 |
Valuation Ratios
The PE ratio is 14.91 and the forward PE ratio is 10.76. Harmony Biosciences 's PEG ratio is 0.08.
| PE Ratio | 14.91 |
| Forward PE | 10.76 |
| PS Ratio | 3.3 |
| Forward PS | 2.1 |
| PB Ratio | 4.11 |
| P/FCF Ratio | 8.77 |
| PEG Ratio | 0.08 |
Enterprise Valuation
Harmony Biosciences Inc. has an Enterprise Value (EV) of 1.80B.
| EV / Earnings | 13.99 |
| EV / Sales | 3.1 |
| EV / EBITDA | 8.14 |
| EV / EBIT | 9.39 |
| EV / FCF | 8.23 |
Financial Position
The company has a current ratio of 2.75, with a Debt / Equity ratio of 0.41.
| Current Ratio | 2.75 |
| Quick Ratio | 2.72 |
| Debt / Equity | 0.41 |
| Total Debt / Capitalization | 29.3 |
| Cash Flow / Debt | 1.13 |
| Interest Coverage | 8.08 |
Financial Efficiency
Return on equity (ROE) is 0.28% and return on capital (ROIC) is 21.6%.
| Return on Equity (ROE) | 0.28% |
| Return on Assets (ROA) | 0.16% |
| Return on Capital (ROIC) | 21.6% |
| Revenue Per Employee | 2.37M |
| Profits Per Employee | 523.79K |
| Employee Count | 246 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 22.61 |
Taxes
| Income Tax | 44.54M |
| Effective Tax Rate | 0.26 |
Stock Price Statistics
The stock price has increased by 17.97% in the last 52 weeks. The beta is 0.77, so Harmony Biosciences 's price volatility has been higher than the market average.
| Beta | 0.77 |
| 52-Week Price Change | 17.97% |
| 50-Day Moving Average | 34.77 |
| 200-Day Moving Average | 33.55 |
| Relative Strength Index (RSI) | 60.63 |
| Average Volume (20 Days) | 781.90K |
Income Statement
In the last 12 months, Harmony Biosciences had revenue of 582.02M and earned 128.85M in profits. Earnings per share was 2.17.
| Revenue | 582.02M |
| Gross Profit | 460.79M |
| Operating Income | 192.03M |
| Net Income | 128.85M |
| EBITDA | 221.51M |
| EBIT | 192.03M |
| Earnings Per Share (EPS) | 2.17 |
Balance Sheet
The company has 311.66M in cash and 193.57M in debt, giving a net cash position of 118.09M.
| Cash & Cash Equivalents | 311.66M |
| Total Debt | 193.57M |
| Net Cash | 118.09M |
| Retained Earnings | -143.28M |
| Total Assets | 928.13M |
| Working Capital | 361.13M |
Cash Flow
In the last 12 months, operating cash flow was 219.39M and capital expenditures -312.00K, giving a free cash flow of 219.07M.
| Operating Cash Flow | 219.39M |
| Capital Expenditures | -312.00K |
| Free Cash Flow | 219.07M |
| FCF Per Share | 3.68 |
Margins
Gross margin is 79.17%, with operating and profit margins of 32.99% and 22.14%.
| Gross Margin | 79.17% |
| Operating Margin | 32.99% |
| Pretax Margin | 29.79% |
| Profit Margin | 22.14% |
| EBITDA Margin | 38.06% |
| EBIT Margin | 32.99% |
| FCF Margin | 37.64% |
Dividends & Yields
HRMY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 5.7% |
| FCF Yield | 10.09% |
Analyst Forecast
The average price target for HRMY is $54, which is 41.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $54 |
| Price Target Difference | 41.8% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | 5.7 |
| Piotroski F-Score | 7 |